EUVIMEDEUVIMED entdecken
Crossref

Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations

Zheng Qian iD, Anni Liu, Jinjin Yang, Jiamin Qin, Wei Chen, You Ge, Yandan Zhong, Hongxia Wei, Yaling Chen, Zhiliang Hu

HIV Medicine · 2026-07 · 27 (7) · 1196-1202

DOI: 10.1111/hiv.70249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 28.04.2026. Verfasst von Zheng Qian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Emtricitabine, HIV-1. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Innovation Center for Infectious Diseases of Jiangsu Province, Jiangsu Provincial Health Commission Medical Research Foundation, General Clinical Trial Project of the Nanjing Medical Science and Technology Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Accumulating evidence supports switching virologically suppressed people with HIV (PWH) harbouring nucleoside reverse transcriptase inhibitor (NRTI) resistance‐associated mutations (RAMs) to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). However, real‐world data on initiating B/F/TAF in individuals with NRTI RAMs and ongoing viremia remain limited.

Methods

We retrospectively included adult PWH treated at the Second Hospital of Nanjing between June 2020 and November 2024 who had at least one NRTI RAM and an HIV‐1 RNA ≥200 copies/mL at B/F/TAF initiation. The primary outcome was virological suppression at 12 months (HIV‐1 RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralEmtricitabineHIV-1Anti-HIV AgentsTenofovirReverse Transcriptase InhibitorsAdenineHeterocyclic Compounds, 4 or More RingsHumansMaleFemaleAdultRetrospective StudiesMutationMiddle AgedViremiaViral LoadPyridonesDrug SubstitutionAlanineAmidesHeterocyclic Compounds, 3-RingPiperazines

Stichwörter der Autor:innen

HIV‐1bictegravir/emtricitabine/tenofovir alafenamidereal‐world studyresistance‐associated mutationsvirological suppression

Substanzen

EmtricitabineAnti-HIV AgentsTenofovirbictegravirReverse Transcriptase InhibitorsPyridonesAdenineHeterocyclic Compounds, 4 or More Ringstenofovir alafenamideAlanine

Autor:innen und Institutionen

  • Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
  • School of Public Health, Nanjing Medical University, Nanjing, China.
  • Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.

ORCID-Profile: Zheng Qian

Förderung

  • Innovation Center for Infectious Diseases of Jiangsu Province
  • Jiangsu Provincial Health Commission Medical Research Foundation
  • General Clinical Trial Project of the Nanjing Medical Science and Technology Development Fund

Zitieren

APA

Qian, Z., Liu, A., Yang, J., Qin, J., Chen, W., Ge, Y., Zhong, Y., Wei, H., Chen, Y., & Hu, Z. (2026). Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations. HIV Medicine, 27(7), 1196-1202. https://doi.org/10.1111/hiv.70249

Vancouver

Qian Z, Liu A, Yang J, Qin J, Chen W, Ge Y, et al. Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations. HIV Medicine. 2026;27(7):1196-1202. doi:10.1111/hiv.70249

BibTeX
@article{Qian2026,
  author = {Qian, Zheng and Liu, Anni and Yang, Jinjin and Qin, Jiamin and Chen, Wei and Ge, You and Zhong, Yandan and Wei, Hongxia and Chen, Yaling and Hu, Zhiliang},
  title = {Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations},
  journal = {HIV Medicine},
  year = {2026},
  volume = {27},
  number = {7},
  pages = {1196--1202},
  doi = {10.1111/hiv.70249}
}
Kostenlos starten →